Antibody Drug Conjugates Contract Manufacturing Market Size (2024 - 2029)

Antibody Drug Conjugates Contract Manufacturing Market Analysis

The Antibody Drug Conjugates Contract Manufacturing Market size is estimated at USD 8.44 billion in 2024, and is expected to reach USD 30.84 billion by 2029, growing at a CAGR of 29.60% during the forecast period (2024-2029).

The COVID-19 pandemic had an enormous influence on the healthcare domain, significantly disrupting the whole supply chain, from raw materials to production and delivery. An optimistic and conscious approach to the development of monoclonal antibodies and other ADCs was driven into the spotlight as potential treatments for COVID-19. The pandemic created a sturdy and quick reaction from scientists working for governments and industries to produce medicines and vaccines. As a consequence of the demand for effective medicines for the treatment of COVID-19, the global production of antibody-drug conjugates, vaccines, and other pharmaceuticals expanded. Besides, ADCs are more complex to manufacture, which is likely to create more demand for contract manufacturing organizations.

Antibody-drug conjugates are complex, potent biologics that offer significant potential to address critical diseases, including cancer. The clinical potential of these therapeutics is attributed to their ability to effectively target disease-associated cells while minimizing off-target toxicity. Notably, with time and advancements in research, scientists have further improved the design and development process for these therapies. This has resulted in the approval of four new ADCs in 2020. To date, the USFDA has approved 12 antibody-drug conjugates, and 100 are in development.

Also, as per the ADC Review in 2021, around 70% of antibody-drug conjugate projects are outsourced to contract development and manufacturing organizations (CDMOs), and with the continued expansion of the pipelines, this trend is likely to endure further. As more commercial products reach the market, there is an acute need for contract development and manufacturing organizations that know the way to execute late-stage studies to support the filing strategy. CMOs, with plans to support commercial-scale antibody-drug conjugate manufacturing by setting up processes to handle challenging supply chains by investing in facilities and processes to ensure security, quality, and efficiency, are expected to contribute to the growth of the market over the forecast period. Hence, given the anticipated growth in the demand for antibody-drug conjugates, the contract manufacturing market for antibody-drug conjugates is also expected to witness significant growth in the coming years.

Antibody Drug Conjugates Contract Manufacturing Industry Segmentation

Antibody-drug conjugates (ADC) are a class of biopharmaceuticals designed for cancer treatment that comprise an antibody that specifically targets a tumor antigen and a cytotoxic compound associated with a chemical linker. They are intended to allow the precise targeting of the cytotoxic compound to kill tumor cells while having a limited effect on healthy tissue. As ADCs are a novel class of biopharmaceuticals, the production of such complex products requires both chemical and biological know-how. Contract manufacturing organization provides technical knowledge in conjugation and linker creation, as well as solid platforms.

The antibody-drug conjugates contract manufacturing market is segmented by linker (cleavable linker and non-cleavable linker), application (myeloma, lymphoma, breast cancer, and other applications), phase (clinical and commercial), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers values in USD million for the abovementioned segments.